PubRank

Daniela Smaniotto

Author PubWeight™ 15.08‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002 2.27
2 Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002 1.24
3 Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2005 1.09
4 Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiat Oncol Biol Phys 2007 0.95
5 Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004 0.86
6 Lymph node involvement in locally advanced cervical cancer patients administered preoperative chemoradiation versus chemotherapy. Ann Surg Oncol 2007 0.84
7 Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study. Am J Clin Oncol 2008 0.82
8 External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 2009 0.82
9 Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma. Ann Surg Oncol 2012 0.82
10 Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Gynecol Oncol 2006 0.82
11 Radiotherapy-related fatigue: incidence and predictive factors. Rays 2005 0.81
12 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study. Int J Radiat Oncol Biol Phys 2004 0.80
13 Radiation-induced cardiovascular disease: impact of dose and volume. Rays 2005 0.77
14 Lymphatic drainage and CTV in pancreatic carcinoma. Rays 2004 0.77
15 Neoadjuvant chemoradiation followed by radical hysterectomy in FIGO Stage IIIB cervical cancer: feasibility, complications, and clinical outcome. Int J Gynecol Cancer 2009 0.76
16 Lymphatic drainage and CTV in carcinoma of the prostate. Rays 2004 0.75
17 Complete response after chemoradiation in ampullary carcinoma: a case report. Tumori 2003 0.75
18 Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology 2004 0.75
19 Radiotherapy in cT3 prostatic carcinoma: retrospective comparison between neoadjuvant and adjuvant hormonotherapy. Urol Int 2004 0.75
20 Biological optimization of the dose in pancreatic cancer. Rays 2004 0.75
21 Biological factors and therapeutic modulation in prostate cancer radiotherapy. Rays 2003 0.75
22 Chemoradiation in cervical carcinoma: a must? Expert Rev Anticancer Ther 2002 0.75
23 Biological factors and therapeutic modulation in pancreatic carcinoma radiotherapy. Rays 2003 0.75
24 Hormono-radiotherapy in prostatic carcinoma: prognostic factors and implications for combined modality treatment. Tumori 2003 0.75
25 Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure. Strahlenther Onkol 2003 0.75